Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.
Dr. Amy Paller shares her opinion on the need for treatment with biologics of children with atopic dermatitis. She highlights that children with moderate-to-severe disease have the greatest risk of persistance, and that they have a high disease burden. She notes that advanced systemic therapies with a good safety profile are available or under evaluation, and that early intervention may help to change the course of disease.
Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US
See author’s profile